STOCK TITAN

ASTELLAS PHARMA UNSP/ADR - ALPMY STOCK NEWS

Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.

Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.

The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
-
Rhea-AI Summary

Astellas Pharma announced the publication of results from the Phase 3 SPOTLIGHT trial evaluating zolbetuximab in combination with mFOLFOX6 for patients with CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. Published in The Lancet, the trial met its primary endpoint of progression-free survival (PFS) and secondary endpoint of overall survival (OS). Key findings include a 24.9% reduced risk of progression or death and a median PFS of 10.61 months for zolbetuximab versus 8.67 months for placebo. OS data revealed a 25% reduced risk of death, with median OS of 18.23 months for the treatment group. The SPOTLIGHT study establishes the clinical benefit of zolbetuximab, supporting Astellas' development efforts in gastric cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $10.09 as of November 22, 2024.

What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?

The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 19.1B.

What is Astellas Pharma Inc. known for?

Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.

What recent achievements has Astellas Pharma Inc. made?

Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.

What is zolbetuximab, and why is it significant?

Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.

How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?

Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.

What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?

Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.

ASTELLAS PHARMA UNSP/ADR

OTC:ALPMY

ALPMY Rankings

ALPMY Stock Data

19.11B
1.79B
0.02%
Drug Manufacturers - General
Healthcare
Link
United States of America
Tokyo